IRIS PubliCatt

Salutari, Vanda
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.265
EU - Europa 1.160
AS - Asia 734
SA - Sud America 20
AF - Africa 10
OC - Oceania 2
Totale 3.191
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.255
CN - Cina 407
DE - Germania 338
SG - Singapore 202
IT - Italia 199
SE - Svezia 196
IE - Irlanda 89
UA - Ucraina 68
PL - Polonia 55
ID - Indonesia 53
FR - Francia 46
RU - Federazione Russa 38
FI - Finlandia 35
GB - Regno Unito 27
IN - India 21
BR - Brasile 17
NL - Olanda 14
TR - Turchia 14
BE - Belgio 12
AT - Austria 11
CA - Canada 7
JP - Giappone 7
CI - Costa d'Avorio 6
KR - Corea 6
CH - Svizzera 5
CZ - Repubblica Ceca 5
HK - Hong Kong 4
IR - Iran 4
VN - Vietnam 4
LT - Lituania 3
BG - Bulgaria 2
IL - Israele 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
MK - Macedonia 2
MX - Messico 2
NO - Norvegia 2
TJ - Tagikistan 2
AL - Albania 1
AR - Argentina 1
AU - Australia 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BZ - Belize 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
IS - Islanda 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MT - Malta 1
NZ - Nuova Zelanda 1
PE - Perù 1
RO - Romania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
Totale 3.191
Salva come PNG Salva come JPEG
Città #
Chandler 249
Hangzhou 183
Ashburn 134
Singapore 129
Dublin 89
Beijing 63
San Mateo 54
Warsaw 52
Jakarta 51
Wilmington 48
Ann Arbor 46
Jacksonville 43
New York 42
Redmond 33
Nanjing 31
Rome 29
Bremen 25
Boston 24
Dearborn 24
Moscow 24
Cattolica 23
Houston 23
Milan 23
Princeton 21
Nürnberg 20
Fairfield 19
Helsinki 18
Los Angeles 17
Munich 16
Redwood City 16
Seattle 15
Marseille 13
Nanchang 13
Woodbridge 13
Izmir 12
Lawrence 12
Shenyang 12
Brussels 10
Naples 10
Washington 9
Boardman 8
Cambridge 8
Jiaxing 8
Kunming 7
Mountain View 7
University Park 7
Vienna 7
Abidjan 6
Bologna 6
Detroit 6
Falkenstein 6
Zhengzhou 6
Albano Laziale 5
Guangzhou 5
Leawood 5
Amsterdam 4
Andover 4
Cosenza 4
Hebei 4
Hong Kong 4
New Haven 4
Shanghai 4
Asti 3
Busto Arsizio 3
Changsha 3
Dong Ket 3
Guiyang 3
Jeju City 3
Lanzhou 3
Norwalk 3
Nuremberg 3
Olomouc 3
Ottawa 3
Paris 3
Simi Valley 3
Tacoma 3
Altamura 2
Augusta 2
Bari 2
Brno 2
Council Bluffs 2
Dushanbe 2
Groningen 2
Guidonia Montecelio 2
Hefei 2
Hyderabad 2
Jinan 2
Lancaster 2
London 2
Marietta 2
Nave 2
Nishio 2
Okayama 2
Osimo 2
Phoenix 2
Polska 2
Prineville 2
Pune 2
Riga 2
Sacramento 2
Totale 1.903
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 454
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 310
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 258
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results 180
Early detection of recurrence or progression disease in patients with ovarian cancer after primary debulking surgery: a diagnostic challenge still unresolved. Correlation between CT findings and CA 125 levels. 142
A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations 139
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. 137
The 'lead vessel': a vascular ultrasound feature of metastasis in the ovaries. 103
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). 102
"Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging 97
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 94
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 87
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study 86
Optimizing treatment in recurrent epithelial ovarian cancer 74
Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study 63
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 59
New medical approaches in advanced ovarian cancer 57
Controversy in treatment of advanced ovarian cancer 55
Combining targeted therapies in ovarian cancer 54
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 54
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 53
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 52
Immunotherapy-related imaging findings in patients with gynecological malignancies: What radiologists need to know 51
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: A phase II, open label multicenter study (NUVOLA trial) 49
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 46
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 42
Newly diagnosed ovarian cancer: Which first-line treatment? 42
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 41
A retrospective analysis of trabectedin infusion by peripherally inserted central venous catheters: A multicentric Italian experience 40
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 39
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 39
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 38
PARP Inhibitors Resistance: Mechanisms and Perspectives 37
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinumbased chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 37
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 37
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 36
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 35
Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience" 35
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 34
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 32
Recent progress in the use of pharmacotherapy for endometrial cancer 32
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 31
Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients 30
Advanced and recurrent endometrial cancer: State of the art and future perspectives 28
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 27
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 20
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 20
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience 16
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 15
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 14
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial) 10
Totale 3.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.266
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020204 0 0 0 0 0 0 0 0 67 40 49 48
2020/2021383 36 24 5 23 50 32 40 30 22 45 59 17
2021/2022286 39 16 2 15 17 6 3 60 5 13 54 56
2022/2023722 67 98 46 104 58 93 27 50 94 20 41 24
2023/2024511 20 131 29 35 18 82 48 15 4 20 53 56
2024/2025490 28 17 82 39 71 38 40 46 129 0 0 0
Totale 3.663